Clinical Trial Update: A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 study evaluating valemetostat in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma; recruitment is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)
• valemetostat (valemetostat)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lymphoma | Phase 1, Phase 2 | Status: RECRUITING